This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Trametinib in treating patients with progressive m...
Clinical trial

Trametinib in treating patients with progressive metastatic hormone-resistant prostate cancer

Read time: 3 mins
Last updated:1st Sep 2016
Identifier: NCT02881242

This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer
 

Arms Assigned Interventions
Experimental: Treatment (trametinib)
Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Drug: Trametinib
Given PO
Other Names:
  • GSK1120212
  • JTP-74057
  • MEK Inhibitor GSK1120212
  • Mekinist
Category Value
Date last updated at source 2016-08-25
Study type(s) Randomised clinical trial
Expected enrolment 62
Study start date 2016-09-01
Estimated primary completion date 2019-09-01

View full details